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Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled
Clinical Trial
Peter H. Jongerius, MD*; Frank J.A. van den Hoogen, MD, PhD‡; Jacques van Limbeek, MD, PhD§;
Fons J. Gabree¨ls, MD, PhD*; Karen van Hulst, BSc; and Jan J. Rotteveel, MD, PhD
ABSTRACT. Objective. To investigate the clinical ef-
fectiveness of botulinum neurotoxin type A (BoNT) to
reduce drooling in children with cerebral palsy (CP).
Methods. A controlled clinical trial was performed in
which the results of single-dose BoNT injections in the
submandibular glands were compared with treatment
with scopolamine. Forty-five children who had CP and
experienced severe drooling were enrolled. Drooling se-
verity was measured at baseline, during application of
scopolamine, and at different intervals after BoNT injec-
tions up to 24 weeks, using the Drooling Quotient (DQ),
the Teacher Drooling Scale (TDS), and Visual Analog
Scales (VAS).
Results. Drooling was reduced during scopolamine
application as well as after BoNT injections. Compared
with baseline, the mean DQ showed a significant de-
crease throughout the study. Greatest reductions were
achieved 2 to 8 weeks after BoNT injection. No signifi-
cant differences were found between scopolamine mea-
surements and those up to 24 months after BoNT injec-
tion. Using VAS, parents recorded the effect on drooling
in which significant differences were found between
baseline VAS score and all follow-up assessments. Ac-
cording to our definition of “success to therapy,” de-
manding a 2-point decrease on the TDS, 61.5% of patients
responded to BoNT injections. Analysis of the DQ dem-
onstrated a response rate of 53% of the patients to sco-
polamine and 48.7% to BoNT until 24 weeks after BoNT
injections, the actual duration of this study. As a reaction
to scopolamine, 71.1% of the patients had moderate to
severe side effects. Only nonsevere, incidental side ef-
fects were reported after BoNT injections.
Conclusions. During scopolamine application as well
as after intraglandular BoNT injections, a clinically rele-
vant reduction in drooling was achieved in children with
CP, demonstrating maximum effect 2 to 8 weeks after
injections. This is the first controlled clinical trial that
confirmed a significant effect of BoNT injections in the
treatment of drooling. General anesthesia was needed for
all children. BoNT injections show fewer and less serious
side effects than transdermal scopolamine treatment. Pe-
diatrics 2004;114:620–627; salivary flow, drooling, cerebral
palsy, botulinum toxin, child.
ABBREVIATIONS. CP, cerebral palsy; DQ, Drooling Quotient;
TDS, Teacher Drooling Scale; BoNT, botulinum neurotoxin type
A; VAS, Visual Analog Scales; WCS, worst-case scenario;
MANOVA, multivariate analysis of variance.
Drooling is an important clinical problem in10% to 38% of patients with cerebral palsy(CP).1–3 Insufficient control of the coordinate
mechanism of orofacial, palatolingual, and head and
neck musculature results in excessive pooling of sa-
liva in the anterior part of the oral cavity and unin-
tentional saliva loss.4 Hypersalivation is generally
not the case in children with CP. Direct saliva collec-
tion can be performed by the swab method in which
absorbent cotton rolls are placed directly at the ori-
fices of the glands for 5-minutes. The flow rate can be
calculated by the following formula: salivary flow
rate (mg/min)  (weight increase of rolls [mg]/time
of collection [min]).5,6
The clinical evaluation of drooling severity and
frequency is difficult because of within-subject fluc-
tuation during the day and a large between-subject
variation. Several systems have been used and advo-
cated for assessment of the extent of drooling. Since
its introduction, various modifications of the Drool-
ing Quotient (DQ) have been used.7–13 The DQ is a
validated, semiquantitative, direct observational
method (see Methods).7,14 Rating scales such as the
Teacher Drooling Scale (TDS) have been designed to
assess drooling severity and frequency. The TDS is a
useful tool for outpatient visits.15
The management of drooling remains a problem.
Despite effective treatment modalities to diminish
saliva production, drooling may persist. Many fac-
tors contribute to the saliva passage from the oral
cavity to the esophagus, such as the child’s mental
abilities, the cognitive awareness of social norms, an
intact swallowing mechanism, oral sensibility, lip
closure, and the ability to hold the head in an upright
position. In addition, variables that may influence
salivary flow rate are medication, circadian rhythms,
prestimulation, gender, age, psychological effect,
and general health.16–21 The effective reduction of
saliva production is relevant to the patient only
when the treatment leads to a clinically apparent
diminished drooling.
Conservative treatments as well as surgical proce-
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dures all have their limitations.22 Recent reports sug-
gested botulinum neurotoxin type A (BoNT) injec-
tions into the salivary glands as an option for
treatment of drooling.6,9,10 These reports are case
series and small cohort studies that lack the power to
prove the efficacy of BoNT injections. Ellies et al23
studied a larger population and concluded that the
BoNT effect lasted for 2 to 3 months. From the
pharmacologic profile of BoNT, an appreciable anti-
cholinergic effect can be expected. In particular, type
A toxin cleaves SNAP-25, an enzyme involved in the
release of acetylcholine at the presynaptic membrane
of parasympathetic nerves. In this way, a temporary
denervation of the target organ is established. Botu-
linum toxin is known to give clinically relevant re-
sults for 9 to 12 months in other conditions involving
the autonomic nervous system, for example hyper-
hidrosis.24,25 Although BoNT has been suggested for
clinical use in the treatment of drooling, uncertainty
remains about the clinical effect and duration.
In this study, a controlled clinical trial on the treat-
ment of drooling was performed in which BoNT
injections in the submandibular glands were com-
pared with scopolamine treatment. Difference scores
of semiquantitative measurements of drooling (DQ,
TDS, Visual Analog Scales [VAS]) were analyzed.
The null hypothesis that the effect on drooling would
not differ between scopolamine and BoNT was
tested.
METHODS
Forty-five children with the diagnosis CP were recruited from
the outpatient clinic and enrolled in the study between January
2000 and November 2001. Consecutive patients were included
during a qualification period in which inclusion criteria and ex-
clusion criteria were examined (Table 1).
A score of 3 or higher on the TDS (Table 2) was mandatory to
be included in the study.15 All drugs used were evaluated care-
fully to assess their influence on saliva secretion. Drugs to treat
drooling had to be stopped at least 3 months before participation.
Throughout the study, no medication that could influence the
severity of drooling was allowed. No requirements were set with
regard to the child’s level of mental development.
Possible adverse effects and risks related to the interventions
during the study were explained to the parents. Written informed
consent was obtained. The Hospital’s Human Research Commit-
tee approved the study.
Study Design
The study was executed as a controlled, open-label, clinical
trial. The difference between the 2 episodes of treatment had to be
at least 1 SD. Drooling evaluation (see Procedures) was performed
during baseline, scopolamine application, and after BoNT injec-
tions into the submandibular glands. The sequence of interven-
tions had a fixed order: scopolamine before BoNT. This was cho-
sen because the washout period of scopolamine is known,
whereas the duration of the supposed effect of BoNT needed to be
determined. An independent employee assessed the primary out-
come parameters blinded for the status of the participating pa-
tients, which was achieved by varying the number of baseline
measurements among the patients according to a predetermined
schedule.
In view of side effects of scopolamine, the protocol anticipated
that some of the patients might not complete the scopolamine
period. When scopolamine was used for 48 hours, the patient
was considerate a dropout. When scopolamine was discontinued
48 hours after start, the patient remained in the study, provided
that a control measurement was obtained within the first 24 hours
after discontinuation of the therapy.
Patients returned for follow-up measurements at 2, 4, 8, 16, and
24 weeks after BoNT injections. Patients had to have undergone at
least 1 of the scheduled investigations at 2, 4, or 8 weeks. At least
3 of 5 visits within the first 24 weeks after BoNT injections had to
be conducted.
If a patient was excluded during the use of scopolamine or
during the washout period, it was planned to contact the parents
by telephone after 2 and 4 weeks to check for adverse effects or
other complaints. Dropouts after the BoNT injections were to be
contacted monthly until 24 weeks after injection.
Procedures
A scopolamine patch (Scopo-derm TTS; Novartis Consumer
Health BV, Breda, Netherlands) was placed behind the ear and
changed within every 72 hours. An assessment was scheduled on
the 10th day, with the 4th plaster in situ being applied no longer
than 48 hours before. After a washout period of 2 to 4 weeks, the
child was admitted for outpatient treatment. Using general anes-
thesia for all patients, a single dose of botulinum toxin (Botox;
Allergan, Nieuwegein, Netherlands), reconstituted with 0.9% so-
dium chloride solution, was injected bilaterally in the submandib-
ular glands using a 25-G needle (Spinocan) and a 1-mL syringe.
Weight-dependent dosages were injected in each gland: 15
U/gland for children who weighed 15 kg, 20 U/gland for chil-
dren with a body weight of between 15 kg and 25 kg, and 25
U/gland for children who weighed 25 kg. On injection, each
dose was fractionated and divided over minimally 3 sites in the
gland. Ultrasound guidance was performed using a system (SAL
250; Toshiba Medical Systems Corporation, Tokyo, Japan)
equipped with a 7.5-MHz transducer. Only the submandibular
glands were injected. It is generally accepted that these glands
produce 60% to 70% of secreted resting saliva when the individual
is not eating or drinking.26 Saliva that is produced during eating
and drinking is produced mainly by the parotid glands, with
which we did not want to interfere. The sublingual glands, con-
tributing up to 5% to the total saliva production, were not treated.
After BoNT, parents were asked to register all possible side
effects in a diary. These were discussed during outpatient visits.
Assessment of Drooling
The DQ and VAS served as the primary outcome measures for
this study. The TDS, scored on an ordinal scale, was used to give
supportive evidence for the efficacy of BoNT.
TABLE 1. Inclusion and Exclusion Criteria
Inclusion criteria
Children (male and female) of preschool and school age
(subjects aged 3–18 y)
Diagnosis of CP
A score of 3 on the TDS, indicating severe drooling38
All medication, taken to treat drooling, stopped at least 3 mo
before start of the study
Minimal body weight 8 kg
Informed consent obtained
Caregivers have high enough cognitive ability to participate
in the study
Readiness to participate for 8 mo
Exclusion criteria
Child is enrolled in another medical study
Previous surgical procedures in the oral/nasal cavity
interfering with saliva production
Treatment with BoNT for another indication in the previous 6
mo
Known hypersensitivity to Botox or any part of the
formulation
Use of drugs that interfere with saliva secretion
Known systemic diseases (bronchial asthma, congenital heart
failure, and myasthenia gravis)
TABLE 2. TDS
1 No drooling
2 Infrequent drooling; small amount
3 Occasional drooling; intermittent all day
4 Frequent drooling but not profuse
5 Constant drooling; always wet
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The DQ was scored according to its original design during 2
periods of 10 minutes separated by a 60-minute break.7 An epi-
sode of drooling was defined as new saliva present on the lip
margin or dropping from the chin.12 Every 15 seconds (40 obser-
vations in 10 minutes), the presence or absence of drooling was
assessed. Patients were evaluated at least 1 hour after a meal while
awake and sitting erect. Two speech therapists were especially
trained to execute the measurements. Separate observations were
made during different activities: 1 with the child watching televi-
sion and 1 during an activity, as chosen by the child, that de-
manded a higher level of concentration or physical effort. The
mean of the 2 observations was used for analysis to provide an
outcome on a numeric scale.
The DQ was expressed as a percentage estimated from the ratio
of observed drooling episodes and the total number of observa-
tions (DQ [%]  100  number of drooling episodes/40).8 DQ
assessments were made at baseline, during the use of scopol-
amine, at washout after ending scopolamine therapy, and at reg-
ular intervals after BoNT injections (2, 4, 8, 16, and 24 weeks).
After receiving specific instructions, parents filled out VAS to
investigate therapy results as experienced in the home situation.
Scales of exactly 10 cm without visible subdivisions were pre-
sented on which the average degree of drooling severity during
the 10 to 14 days before assessment had to be indicated. A mark at
the left end represented severe drooling; a mark at the right end
meant no drooling. An independent employee scored the VAS
with a ruler in millimeters, resulting in a number ranging from 0
to 100, which was handled as a parametric variable. VAS assess-
ment was made at baseline, during the use of scopolamine, and at
regular intervals after BoNT injections (4, 8, 16, and 24 weeks).
The TDS (Table 2) was used to assess the degree of drooling by
interviewing the parents or caregivers during outpatient visits.15
Assessments of TDS were made at baseline and after BoNT injec-
tions (8 and 24 weeks). Before analysis of the data, a significant
reaction to therapy was defined as a 2-point improvement on the
TDS (range: 1–5; Table 2). The outcome after BoNT injections is
used only to support the findings in the DQ and VAS data.
Statistics
A power analysis was performed before start of the study.
Approximately 40 patients were needed to reach a power of 80%
with an  of .05. The difference between the 2 episodes of treat-
ment had to be at least 1 SD. Assuming a dropout percentage of
7%, the inclusion of 45 patients was sufficient. Because of the
complexity of the design and vulnerability of the patients, missing
data were inevitable. For this reason, data were adjusted in 2
ways: 1) by carrying the last observation forward and 2) by a
worst-case scenario (WCS) system. In the WCS procedure, all
missing data were replaced by baseline values. In this way, the
effect difference between the therapies was “reduced” by intro-
ducing a bias toward the null. The outcomes of both approaches
were compared.
All statistical procedures were conducted with SPSS/pc (ver-
sion 9.0; SPSS, Inc, Chicago, IL). Data analysis included descriptive
statistics; multivariate analysis of variance (MANOVA) of re-
peated measurements to identify patterns of response over time,
using a within-subjects design with the measurement moments as
the variables; and paired-samples t tests to analyze differences of
paired observations (DQ and VAS) at subsequent measurements.
In addition, success of therapy for either scopolamine or BoNT
was defined as a decrease in DQ of at least 50% of the patient’s
baseline value. Frequency analyses were performed to determine
the percentage of responders in the population. A Wilcoxon
signed ranks test was used to analyze changes in TDS (ordinal
scale). For all statistics, a level of significance with a 1-sided P 
.05 was mandatory.
RESULTS
Forty-five children were included: 28 boys and 17
girls (age: 3–17 years; mean: 9.5; SD: 3.7). Eight were
ambulant without aid, 37 had wheelchairs, 22 could
not talk, 29 attended a special education school, and
14 went to a child care center for mentally handi-
capped children. Thirty-four children had mental re-
tardation with a developmental level 6 years as
determined by psychological investigation.
None of the patients was treated with botulinum
toxin before. By the end of the trial, 6 dropouts had
occurred: 4 patients could not fulfill the scopolamine
period, 1 changed antiepileptic medication, and 1 did
not attend the required measurements because of an
intercurrent illness not related to the trial. The results
of 39 patients could be analyzed.
DQ
In the first instance, analyses were executed with
carrying the last observation forward data. Descrip-
tive statistics of the consecutive measurement mo-
ments showed that, compared with baseline, the
mean DQ decreased during scopolamine application
as well as after BoNT injections, which is shown in
Fig 1. With the DQ at each moment in time defined
as the within-subjects variable, a MANOVA with a
repeated measurements design was executed to eval-
Fig 1. DQ: mean in time. Sc indicates application of
Scopolamine; BTX, injection of botulinum toxin.
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uate the pattern of response during the trial (Hotel-
ings trace: F  12.79; df [7.00]; P  .000). An effect
over time was found as depicted in Fig 1 and de-
scribed in additional detail by analysis of difference.
Univariate analyses were executed to analyze fur-
ther interval difference scores. To justify the length of
the washout period, we compared the DQ values at
baseline with the measurements after washout of
scopolamine, using a paired-samples t test. The mean
change in DQ from baseline to washout value was
estimated to be 1.60, which was a nonsignificant
difference (t  0464; df [38]; P  .32, 1 tailed). This
finding minimizes the probability of a carryover ef-
fect from scopolamine treatment to BoNT, indicating
that the length of washout after scopolamine appli-
cation was sufficient.
Changes in DQ (expressed as differences), SD, and
P values between baseline and the subsequent mea-
surements are tabulated in Table 3. All DQ measure-
ments showed a significant decrease (mean differ-
ences: 15.5–21.7; P  .05, based on paired samples t
tests).
The greatest reduction was achieved 2 weeks after
BoNT injections (BoNT-2: mean difference score:
21.7; SD: 18.3; P  .000). The DQ increased slightly
after BoNT-2. At the end of the study, though, a
significant reduction of drooling was still found, sug-
gesting an ongoing effect.
During additional analysis, scopolamine measure-
ments were compared with the measurements after
BoNT injections up to 24 weeks (Table 4). No signif-
icant differences were found (mean differences: 2.2
to 4.1; P  .05, based on paired samples t tests).
Analysis of WCS data did not lead to different results
comparing baseline with both treatments.
According to our definition of success to therapy,
patients could be assigned as a responder when base-
line DQ decreased by 50% or more during the inter-
ventions. Analysis of frequencies was done. During
scopolamine, 53% of the patients were recognized as
responders. Response rates to BoNT were as follows:
BoNT-2, 64.1%; BoNT-4, 43.5%; BoNT-8, 53%; BoNT-
16, 41%; and BoNT-24, 48.7%.
VAS
The analysis of the VAS showed an effect over
time. With the VAS at each moment in time defined
as the within-subjects variable, a MANOVA with a
repeated measurements design was executed to eval-
uate the pattern of response during the trial (Hotel-
ings trace: F  16.55; df [5]; P  .000). Figure 2 shows
the course of the mean scores at the subsequent
measurement moments.
The degree of reported drooling by the parents
declined substantially when baseline numbers (VAS:
19.3; SD: 13.4; range: 2–61) were compared with
measurement during scopolamine application (VAS:
53.6; SD: 13.4; range: 0–96). Measurements scored by
the parents after BoNT demonstrated good results
with a maximum reduction at BoNT-4 (VAS: 49.3;
SD: 24.5; range: 8–93). The VAS score at BoNT-4 was
in the same range as during scopolamine application,
revealing no significant difference (mean difference:
4.2; SD: 31.3; t 0842; df  38; P  .20, 1 tailed).
Analyses of VAS difference scores were performed,
using paired-samples t tests to compare baseline val-
ues with the results after therapy (Table 3). All dif-
ferences were significant, indicating that parents re-
ported diminished drooling throughout the study. In
addition, scopolamine VAS scores were compared
with all subsequent BoNT measurements (Table 4),
using paired-samples t tests. No differences were
found, meaning that the outcomes of both therapies
as reported by the parents were in the same range.
TDS
Patients had to score 3 or higher on the TDS to be
included in the study. At start of the study, 94.9% of
the patients had a score of 5, with the remaining 5.1%
having a score of 4. A success to therapy was defined
as a 2-point improvement on the TDS (see Methods).
The Wilcoxon signed ranks test was used to analyze
changes in TDS over time. Compared with baseline,
a significant decrease was observed at BoNT-8 (Z 
4.8; P .000, 1-tailed) and BoNT-24 (Z4.1; P
.000, 1-tailed). The TDS is an ordinal scale; as such,
the outcome can provide only supportive evidence.
To confirm the outcome, the TDS should show
changes in the same direction as the VAS (Fig 3). The
curve shows that at baseline, all patients were se-
verely drooling (mean: 4.9). Drooling diminished af-
ter BoNT injections. At BoNT-8, the mean score de-
creased to 3, indicating occasional drooling. At
BoNT-24, the mean TDS score equaled 3.8.
The TDS was also used to define success to therapy
(see Methods). An analysis of frequency of scores on
the TDS was made to provide insight into parents’
recognition of the BoNT therapy effect. Eight weeks
after the BoNT injections, TDS scores were as fol-
lows: 1, 15.4%; 2, 28.2%; and 3, 17.9%. This indicates
that 61.5% of the patients were good responders
according to our definition; 15.4% of the children
TABLE 3. Mean Differences Between Baseline and Follow-up Measurements
Pairs of Observation DQ VAS
Difference (SD) Significance* Difference (SD) Significance*
Bl/scopolamine 17.7 (21.2) .000 34.3 (30.9) .000
Bl/BoNT-2 21.7 (18.3) .000
Bl/BoNT-4 16.1 (18.9) .000 30.1 (22.8) .000
Bl/BoNT-8 20.0 (20.5) .000 22.1 (23.9) .000
Bl/BoNT-16 15.5 (19.1) .000 20.5 (24.9) .000
Bl/BoNT-24 15.7 (16.4) .000 13.5 (25.7) .002
Bl indicates baseline.
* Paired-samples t tests, 1-sided P  .05.
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changed only slightly (score: 4). Twenty-three per-
cent of the cases, representing 9 patients, did not
show improvement compared with their initial
score. Eight (20.5%) patients remained at score 5, and
1 (2.5%) patient remained at score 4. None of the
parents reported an increase in drooling severity as a
result of therapy.
None of the patients showed improvement be-
tween BoNT-8 and BoNT-24. TDS frequency scores
at BoNT-24 were as follows: 1, 5.1%; 2, 15.4%; 3,
Fig 2. VAS: mean in time.
Fig 3. TDS: mean in time.
TABLE 4. Mean Differences Between Scopolamine and BoNT Measurements
Pairs of Observation DQ VAS
Difference (SD) Significance* Difference (SD) Significance*
Sc/BoNT-2 4.1 (16.5) .131
Sc/BoNT-4 1.6 (19.2) .604 4.2 (31.3) .405
Sc/BoNT-8 2.4 (21.7) .502 12.2 (30.9) .018
Sc/BoNT-16 2.2 (21.8) .528 13.7 (32.9) .013
Sc/BoNT-24 2.1 (20.2) .529 20.7 (39.9) .002
Sc indicates scopolamine.
* With paired-samples t tests, 1-sided P  .05.
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15.4%; 4, 20.5%; 5, 43.6%. At 24 weeks after BoNT
injections, 35.9% of the parents still reported a good
effect, whereas 43.6% of the children had returned to
baseline value, among them the 20.5% who did not
react to therapy at all.
Side Effects
Parents scored the extent of side effects on a
4-point scale (0  no side effect; 1  mild, not every
day/occurring sometimes; 2  moderate, present
every day; 3 severe side effect, constantly present).
Side effects as a result of scopolamine became appar-
ent within the first 3 days of administration, and
several patients complained of 1 symptom. Ad-
verse effects during application of scopolamine were
reported in 82.2% of cases. Five (11.1%) patients had
mild, 14 (31.1%) patients had moderate, and 18 (40%)
patients had severe side effects.
Most often reported adverse effects were xerosto-
mia (66.7%), restlessness (35.6%), somnolence
(35.6%), blurred vision because of pupillary dilation,
and confusion (20%). Four of the 6 dropouts from the
study had to end their participation because of ad-
verse effects to scopolamine. In all 4 cases, restless-
ness, apparent in their movement performance, and
confusion were the main reasons to terminate sco-
polamine use. After BoNT injections, incidental side
effects were reported. Two (5.1%) patients had a
transient flu-like syndrome that lasted for 2 days.
Another 3 patients complained of mild difficulty
with swallowing.
DISCUSSION
This is the first controlled, clinical trial to evaluate
the treatment of drooling in children with CP by
comparing the efficacy of 2 different anticholinergic
agents: bilateral single-dose BoNT injections into the
submandibular glands and transdermal scopol-
amine. A positive clinical effect from intraglandular
BoNT injections as well as scopolamine application
was found. Scopolamine was expected to have a
greater effect on drooling because of its systemic
availability, influencing the submandibular glands,
the sublingual glands, and the parotid glands apart
form all minor glands within the mucosa of the oral
cavity. As chosen during this trial, BoNT is injected
only focally into the submandibular gland. Never-
theless, the short-term effect on drooling by intrag-
landular BoNT injections was of the same magnitude
as that of scopolamine. This outcome is compatible
with the concept that the submandibular glands pro-
duce a large part of resting saliva. In addition, it
underlines that BoNT has a strong anticholinergic
effect in the target glands.
The outcomes of clinically relevant parameters
(DQ and VAS) were in accordance with each other,
showing a reduction in drooling after both interven-
tions. The parents’ reports about their child’s drool-
ing at home (VAS scores) showed significant change.
A similar positive effect was demonstrated in the
reduction of DQ after BoNT injections up to 24
weeks, the end of the study. Response rates, as ana-
lyzed in the DQ data, were high. Of all patients, 53%
responded during scopolamine, 64.1% responded 2
weeks after BoNT injections, and 53% responded 8
weeks after injections. After 24 weeks, 48.7% of the
patients still responded to BoNT. Success to therapy
was also defined as a 2-point decrease of the TDS as
compared with baseline. Eight weeks after BoNT
injections, 61.5% of the patients could be registered
as responders according to the TDS approach. At the
end of the study (BoNT-24), 35.9% of the patients
were still responding to the BoNT injections.
The outcome of success to therapy as described
with the DQ is based on an objective observation
expressed on a numeric scale. The result of the TDS
is a subjective expression on an ordinal scale. Still,
the results of both observations on BoNT are congru-
ent. Comparable outcomes on drooling in BoNT
studies have been reported in observational stud-
ies.9,10
Transdermally applied scopolamine and oral anti-
cholinergic agents such as glycopyrrolate and benz-
tropine have been widely investigated in the treat-
ment of drooling.8,15,27–34 Lewis et al31 randomly
assigned patients to a 2-week use of scopolamine
patches and placebo patches using a crossover de-
sign. Success to therapy was recorded in 80% of
patients. Blasco and Stansbury28 performed a pro-
spective open-label study in which 90% of the pa-
tients had reduced drooling in response to glycopyr-
rolate, based on the subjective reports by parents.
Bachrach et al27 investigated the results of glycopyr-
rolate among 37 patients in a questionnaire-based
cohort study. Parents were asked to describe the
amount of drooling before medication had begun
and while their child was taking the medication,
using a 5-point scale. A significant improvement was
present in 95% of cases. Mier et al32 used increasing
dosages of glycopyrrolate in a placebo-controlled
clinical trial. According to their definition of success
to therapy, 81% of patients responded to the highest
dosage. The above-mentioned success rates all ex-
ceeded the 53% responders found in the present
study. An explanation for this difference could be
that the definitions of response (a 50% reduction or
more of the DQ, in our study) used in the studies are
not interchangeable.
Disadvantages of systemic anticholinergic drugs
are the many side effects. Severe side effects were
observed in 40% of cases. Symptoms such as xero-
stomia, restlessness, somnolence, blurred vision, and
confusion were apparent in this study, necessitating
ending the therapy in 7% of the participants. In this
way, 4 of 6 dropouts were attributed to scopolamine.
It was theorized that side effects are probably even
underscored in this study population, taking into
account the patients’ inability to present their com-
plaints clearly. Besides, scopolamine was applied for
a relatively short period. Thus, continued use of sco-
polamine in a dosage large enough to treat severe
drooling seems undesirable.
Side effects as a result of anticholinergic therapy
are also described in other studies. Lewis et al31
reported two third of his population to have pupil-
lary dilatation, and 27% demonstrated pruritus or
increased mouthing behavior as a reaction to scopol-
amine. Applying glycopyrrolate, 32.5% of the pa-
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tients had adverse effects of which behavioral
changes (13%) were specified in a percentage.28 Mier
et al32 reported that adverse effects were common,
affecting 69% of the children who took glycopyrro-
late. The identified side effects ranged from 10% to
23%, comprising behavioral changes, facial flushing,
nasal congestion, constipation, vomiting, diarrhea,
dry mouth, urinary retention, and blurred vision.
Seven of 36 participants withdrew from the study
because of side effects. Although side effects seem to
be common in relation to the use of anticholinergic
drugs, the intensity and the occurrence of central
effect may vary, depending on the drug of choice.
BoNT led to temporary complaints about swallow-
ing in 2 cases. This was ascribed to local swelling in
1 patient. In another case, moderate difficulty with
swallowing developed after 1 week and remained
for 10 days. It was theorized that this might have
been the result of diffusion of BoNT into the sur-
rounding muscles. Other authors explicitly noted
that no side effect were seen after BoNT injections.23
BoNT, when accidentally injected next to the sali-
vary glands, will influence neural activity at the neu-
romuscular junction as well. To avoid side effects
and achieve optimal results, ultrasound guidance is
strongly recommended.5,23,35,36 Although easy to
perform, BoNT injections are to some extent inva-
sive. General anesthesia could be regarded as a dis-
advantage. In this respect, it must be emphasized
that other authors performed the procedure without
anesthesia.23
As chosen in our protocol, only the submandibular
glands were treated. However, it must be realized
that there may exist indications to treat the parotids
as well, for example, excessive drooling during eat-
ing and drinking.
To our knowledge, this is the first controlled clin-
ical trial in the treatment of drooling, evaluating the
effect of scopolamine application and intraglandular
BoNT injections into the submandibular glands. Both
treatments significantly reduced drooling compared
with baseline. The outcome of both therapies is in the
same range and, no significant differences were
found between DQ measurements during scopol-
amine and BoNT. A disadvantage in the treatment
with scopolamine is the high percentage of observed
adverse reactions, whereas BoNT injections need
general anesthesia in children. The BoNT effect is
temporary, although longer duration might be ex-
pected especially after recurrent treatment because of
supposed hypotrophy of the glands after long dener-
vation. Referring to the demands about the diagnosis
and TDS, as stated in the inclusion criteria, the gen-
eralizability of this study is limited to comparable
groups of patients. Additional research is needed to
investigate BoNT therapy in other groups and to
compare it with other interventions to treat drooling,
such as surgery. Considering the social burden to the
affected children, it is relevant to develop clinical
guidelines to distinguish types and age groups of
drooling patients to optimize the treatment modali-
ties that are specifically effective.
In conclusion, during scopolamine application and
after intraglandular BoNT injections, a clinically rel-
evant reduction of drooling was achieved in children
with CP, demonstrating maximum effect 2 to 8
weeks after injections. Analysis of the DQ demon-
strated a response rate to scopolamine of 53% and of
nearly 50% until 24 weeks after BoNT injections, the
actual duration of this study. Additional research is
warranted to optimize selection of patients in an
effort to maximize the therapeutic effect.
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BLAME LIFESTYLE FOR MYOPIA EPIDEMIC?
“Contrary to popular belief, people in East Asia are no more genetically suscep-
tible to short-sightedness than any other population group, according to research-
ers who have analyzed the past studies of the problem. The epidemics of myopia
in countries such as Singapore and Japan are due solely to changes in lifestyle, they
say, and similar levels could soon be seen in many western countries as lifestyles
there continue to change. ‘As kids spend more time indoors on computers or
watching telly, we are going to become just as myopic,’ says Ian Morgan of the
Australian National University in Canberra. Myopia is on the increase in most
places, but in countries such as Singapore it has reached extraordinary levels.
There, 80 percent of 18-year-old male army recruits are myopic, up from 25 percent
just 30 years ago. . . . Another study found myopia rates of 80 percent in 14- to
18-year-old boys studying in schools in Israel that emphasize reading religious
texts. The rate for boys in state schools was just 30 per cent. . . . In Sweden, for
instance, 50 percent of children aged 12 now have myopia. It is expected that when
these children reach 18 the rate will be more than 70 percent.”
Nowak R. New Scientist. July 10, 2004
Noted by JFL, MD
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